Effects of Exercise and Metformin on Methylglyoxal Levels in Prediabetic Individuals

Not Applicable

Completed

• Conditions: Methylglyoxal; PreDiabetes; Exercise; Metformin

• Registration Number: NCT06603480
• Lead Sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

Brief Summary

The aim of this study is to compare the effects of exercise, standard lifestyle changes and metformin on MGO in prediabetic individuals.

Detailed Description

There is no comparative study in the literature evaluating the effects of exercise and metformin on MGO in prediabetic patients. The aim of this study is to compare the effects of exercise, standard lifestyle changes and metformin on MGO in prediabetic individuals.

Study Timeline

• Study Start: 2021-04-08
• Primary Completion: 2022-12-07
• Study Completion: 2022-12-07
• Status Verified: 2024-09
• Study First Submitted: 2024-09-13
• Study First Submitted QC: 2024-09-17
• Last Update Submitted: 2024-09-17
• Study First Posted: 2024-09-19
• Last Update Posted: 2024-09-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

• Patients who were newly diagnosed with prediabetes by Oral Glucose Tolerance Test (OGTT) and/or HbA1C,
• who were assessed as physically inactive (Level 1) according to the International Physical Activity Questionnaire
• who had sufficient motivation to participate in the exercise program (assessed by one-on-one interviews conducted by the researchers),
• who were deemed suitable to participate in the exercise program after a cardiac examination by a cardiologist (with resting electrocardiogram and questioning of cardiac symptoms, and advanced tests such as exercise electrocardiogram test when necessary),
• who had the same weight (±2.5 kg) for 6 months before participating in the study.

Exclusion Criteria

• having a serious medical condition that would prevent the person from participating in the exercise study (e.g. advanced malignancy or major neurological, psychiatric or endocrine disease, respiratory failure, etc.),
• having used metformin for 6 months before the study, having cardiovascular disease,
• heart failure, cancer, having a BMI <19 kg/m2, receiving hormone replacement therapy,
• having a life expectancy of less than 1 year, being HIV positive, substance use,
• functional dependence, having an orthopedic disease that prevents physical activity,
• having cognitive impairment and other diseases that would affect the study results (respiratory diseases, muscle diseases, non-alcoholic fatty liver disease, etc.),
• using medications or supplements that would affect the study results.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
MGO	1 week	Methylgloxal level

Trial Locations

Locations (1)

Sultan 2. Abdülhamid Han Training and Research Hospital; 🇹🇷 Üsküdar, İstanbul, Turkey